摘要：pH-sensitive smart polymeric nanocarriers have been under development in the field ofbiomedicine due to permeabilization the physiological barriers readily to address the limitation of conventional chemotherapeutics delivery systems of low intracellular transport and targeting *** traditional polymers kept stable under physiological neutral or acidic conditions,pH-sensitive polymeric nanocarriers underwent rapid degradation with a labile group in tumor acidic environment(around 5.0-6.0),allowing these biomaterials to achieve controlled drug release,drug pharmacokinetics improvement and antitumor biotherapeutic molecules efficiency enhancement compared with traditional *** review mainly concentrated on properties of pH-sensitive polymers for biomedical purposes to construct the smart drug delivery system based on acid liable linkers which were categorized into pH-sensitive polymeric prodrugs composed of antitumor drugs(doxorubicin and paclitaxel)bounded to the polymer via acid liable linkers and pH-sensitive copolymeric nanocarriers prepared by block copolymers containing polymer blocks linked with acid-cleavable ***,advanced platforms in biomedicine for special biotherapeutic molecules delivery were reviewed in the ***,several acid-sensitive linkages were reviewed to study the mechanism of the controlled pH-responsive drug delivery,such as hydrazone,acetal,cis-aconityl linker and β-thioether ester,as well as improvement of drug pharmacokinetics.

摘要：This review is intended to help clinicians design drug regimens for special populations of critically ill patients with extremes of body size, habitus and composition that make drug choice or dosing particularly challenging due to the lack of high-level evidence on which to make wellinformed clinical decisions. The data sources included a literature search of MEDLINE and EMBASE with reviews of reference lists of retrieved articles. Abstracts of original research investigations and review papers were reviewed for their relevance to drug choice or dosing in the following special critically ill populations: patients with more severeforms of bodyweight or height, patients with amputations or missing limbs, pregnant patients, and patients undergoing extracorporeal membrane oxygenation or plasma exchange. Relevant papers were retrieved and evaluated, and their associated reference lists were reviewed for citations that may have been missed through the electronic search strategy. Relevant original research investigations and review papers that could be used to formulate general principles for drug choice or dosing in special populations of critically ill patients were extracted. Randomized studies with clinically relevant endpoints were not available for performing quantitative analyses. Critically ill patients with changes in body size, habitus and composition require special consideration when designing medication regimens, but there is a paucity of literature on which to make drug-specific, high-level evidencebased recommendations. Based on the evidence that is available, general recommendations are provided for drug choice or dosing in special critically ill populations.